Cancer has always been one of the most feared diagnoses, not only in India but across the world. For families in Maharashtra, it has too often meant endless hospital visits, financial ruin, and a journey marked by both physical and emotional exhaustion. The data released by the Indian Council of Medical Research (ICMR) and the National Centre for Disease Informatics and Research (NCDIR) for 2025 paints a disturbing picture: Maharashtra has witnessed an 11 percent rise in cancer cases compared to 2020. Numbers that were once alarming have now become a crisis. Against this backdrop, the state cabinet has cleared a comprehensive cancer care policy that promises to reshape how the disease is treated, studied, and managed. The ambitious plan involves the creation of a new body, the Maharashtra Cancer Care, Research and Education Foundation, better known as the MAHACARE Foundation, which is expected to spearhead a three-tier network of cancer hospitals, research initiatives, education programs, and patient support mechanisms across the state.

The promise of this policy is vast. It envisions 18 hospitals across Maharashtra being structured into three levels of care: L-1, L-2, and L-3 centres. At the top sits Tata Memorial Hospital in Mumbai, identified as the apex L-1 centre, which will act as the nerve centre of cancer care, guiding standards, research, and advanced treatment. The L-2 centres, which include hospitals in Chhatrapati Sambhajinagar, Nagpur, Pune, Kolhapur, Chandrapur, Mumbai, Nashik, and Amravati, will be equipped for radiotherapy, chemotherapy, postgraduate and super-specialty education, surgery, physiotherapy, palliative care, and psychological support. Below them are L-3 hospitals spread across districts such as Ambajogai, Nanded, Yavatmal, Satara, Baramati, Jalgaon, Ratnagiri, and Shirdi, which will serve as referral and treatment hubs connected to the higher centres. The layering of this structure is designed to ensure that no patient, whether in Mumbai or in the smaller towns of Beed or Jalgaon, is left without access to some form of cancer diagnosis and treatment.

On paper, the plan is meticulous. A Command-and-Control Centre will coordinate the functioning of these hospitals, ensuring smooth referral pathways, resource sharing, and accountability. The MAHACARE Foundation will serve as the financial and administrative backbone, receiving an initial capital of ₹100 crore and additional funding from a combination of government programs, Mahatma Phule Jan Arogya Yojana contributions, international agencies, clinical trials, donations, and CSR initiatives. This foundation will not only oversee cancer hospitals but also design localised health programs, awareness campaigns, and preventive strategies aimed at lifestyle modification. It will be tasked with bridging the gaps that have historically plagued cancer care in India with delays in diagnosis, lack of equipment, uneven distribution of oncologists, and unaffordable treatment.

Maharashtra’s cancer care policy comes at a time when India’s oncology infrastructure is already stretched thin. Waiting lines at Tata Memorial can stretch for weeks, sometimes months, forcing patients from rural districts to either postpone treatment or seek private care that drains their savings. An 11 percent rise in cases over five years is not just a number, it represents thousands of new patients entering a system already bursting at the seams. Can a policy alone fix what has long been a structural failure? Will the MAHACARE Foundation manage to deliver the skilled manpower, functioning equipment, and timely care that are essential to make this vision more than another government announcement?

One of the strengths of the new policy lies in its recognition that cancer care cannot be addressed by treatment alone. By including education, research, and palliative care in its mandate, the government is signaling an awareness that oncology is a multi-layered challenge. Cancer is as much about awareness and prevention as it is about surgery and chemotherapy. Lifestyle factors, delayed screenings, and cultural stigmas have long contributed to late-stage diagnoses in India, where curative treatment becomes less effective. The inclusion of research into the policy could mean that Maharashtra begins to develop context-specific strategies, studying the patterns of cancers that dominate its population, whether oral cancers linked to tobacco, cervical cancers preventable through vaccination, or breast cancers that still carry stigma around self-examination.

The emphasis on palliative care is particularly important. Too often in India, the conversation around cancer stops at treatment, with little focus on the quality of life for patients who cannot be cured. Palliative care, when available, is mostly concentrated in metropolitan cities, leaving rural families to cope with pain management and emotional support on their own. By involving NGOs in palliative initiatives, the MAHACARE Foundation could potentially extend dignity and comfort to patients across Maharashtra who would otherwise have none. If executed sincerely, this single aspect of the policy could transform thousands of lives, ensuring that the journey of cancer patients is not only about survival but also about compassion.

However, the challenges that loom are enormous. Funding is the first hurdle. While an initial corpus of ₹100 crore has been promised, anyone familiar with the economics of oncology knows this amount is modest compared to the actual requirements of equipment, advanced drugs, and human resources. A single radiotherapy machine can cost several crores, and hospitals often need multiple machines to manage patient volumes. The promise that 20 percent of fees under the Mahatma Phule Jan Arogya Yojana will be directed to the foundation, along with revenue from clinical trials and CSR, shows creativity in financing, but execution remains key. The risk of bureaucratic delays, mismanagement, or uneven distribution of funds could derail the program before it takes off.

Another looming challenge is manpower. Cancer care requires highly trained oncologists, oncology nurses, radiotherapists, physicists, counselors, and palliative specialists. Maharashtra has long faced a shortage of super-specialists, with many trained doctors migrating to private institutions or abroad. While the policy does mention fellowships in postgraduate and super-specialty education at L-2 hospitals, training the next generation of oncologists is a long-term goal that will take years to bear fruit. The immediate reality is that setting up machines and centres without trained professionals risks creating hollow institutions, buildings filled with equipment but lacking the expertise to use them effectively.

The governance structure of the MAHACARE Foundation, with the Chief Minister as chairman and senior ministers as vice-chairmen, signals the importance attached to the initiative. But it also raises concerns about politicisation. Health programs in India often falter when political agendas override professional decision-making. While the appointment of a Chief Executive Officer with expertise in health services could bring credibility, the success of the foundation will ultimately depend on whether it is allowed to function as a professional body or whether it is weighed down by red tape and political interference. The inclusion of an expert executive board is promising, but its independence will be tested in the years ahead.

The policy also mentions international funding and collaborations. If Maharashtra can attract global partnerships, it could open doors to advanced research, innovative therapies, and exchange of expertise. Clinical trials, often conducted at premier institutes, could become a source of both funding and access to cutting-edge treatments for Indian patients.

Another crucial factor is the integration of these new cancer centres with primary healthcare. For decades, one of the major reasons for late-stage cancer diagnoses in India has been the absence of early detection at the grassroots level. If the new policy focuses solely on tertiary care without linking to community health workers, screening programs, and primary health centres, it risks treating cancer at its most advanced and least curable stages. Awareness campaigns, vaccination drives for HPV, tobacco cessation programs, and regular screening camps must be made a core part of this new cancer policy for it to truly change outcomes.

The promise of research embedded in this policy deserves special attention. By encouraging locally relevant studies, Maharashtra could lead the way in understanding why certain cancers dominate its population, how socio-economic factors shape treatment adherence, and what preventive measures work best in its districts. For too long, Indian cancer research has leaned heavily on global studies that may not reflect the realities of our people. A strong research agenda, supported by MAHACARE, could produce data that not only improves local outcomes but also contributes to national and international oncology knowledge.

Cancer care in Maharashtra has long been a story of inequality where world-class institutions in Mumbai contrasted with bare-bones facilities in rural districts. This policy attempts to rewrite that story by creating a structured, state-wide ecosystem. It is bold, it is necessary, and it is filled with potential. But as every doctor knows, diagnosis is only the first step. Treatment requires consistency, discipline, and follow-through. The state has diagnosed the crisis. The real treatment begins now.